Free Newsletter
IV Relenza saves U.K. woman from H1N1 flu
Free newsletter via e-mail
Tools
Mainlining GlaxoSmithKline's Relenza could end up as the swine-flu treatment of last resort. British doctors saved the life of a woman with severe H1N1 flu, using an unapproved IV form of the Glaxo antiviral. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: